Effect of Noninvasive Ventilation on Physical Activity and Inflammation in COPD Patients

NCT ID: NCT01037387

Last Updated: 2023-03-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE4

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-12-31

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Parallel, randomized and controlled clinical trial to evaluate the effect of 12 months of noninvasive mechanical ventilation versus conventional treatment in hypercapnic patients with stable COPD.

Main objective: To evaluate the effect of 12 months of noninvasive ventilation on c-reactive protein concentration and daily physical activity in hypercapnic patients with stable COPD.

Secondary objectives: To compare the plasmatic concentration of other inflammatory biomarkers between COPD patients with conventional treatment and wich noninvasive ventilation. To determine the response of breathlessness, health-related quality of life and lung function to noninvasive ventilation. To identify the COPD patients with a higher gasometric and clinic response to noninvasive ventilation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Obstructive Pulmonary Disease Hypercapnic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control

Conventional treatment for COPD

Group Type ACTIVE_COMPARATOR

Control

Intervention Type DRUG

Current treatment according to the ATS/ERS guidelines

NIMV group

NIMV: Conventional treatment plus noninvasive mechanical ventilation

Group Type EXPERIMENTAL

NIMV group

Intervention Type DEVICE

Current treatment according to the ATS/ERS guidelines and nocturnal BiPAP (IPAP 10-20 cmH2O,EPAP 4-6 cmH2O).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Control

Current treatment according to the ATS/ERS guidelines

Intervention Type DRUG

NIMV group

Current treatment according to the ATS/ERS guidelines and nocturnal BiPAP (IPAP 10-20 cmH2O,EPAP 4-6 cmH2O).

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Bronchodilator agents and inhaled corticosteroids Bronchodilator agents and inhaled corticosteroids.

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age: 45-75 yrs.
* COPD diagnosis (postbronchodilator FEV1/FVC \< 0.7) for at least 6 months.
* FEV1 \< 45% predicted
* Baseline pH 7.35-7.45
* Baseline PaCO2\>45 mmHg breathing current air
* Smoking history (\>15 pack-year)
* Clinically stable for at least the last three months
* Pharmacological treatment optimized in the last two years.

Exclusion Criteria

* Previous diagnosis of asthma, other airway obstructive disease, sleep apnea syndrome, interstitial lung disease, chest wall disease or neuromuscular disease.
* Apnea-hypopnea index \> 10/h
* Morbid obesity (BMI \> 45 Kg/m2)
* Previous diagnosis of ischaemic heart disease, cardiac failure, cirrhosis, chronic renal failure, rheumatoid arthritis or other inflammatory disease.
Minimum Eligible Age

45 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hospital Universitario La Paz

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Francisco Garcia-Rio

MD

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Maria Antonia Gómez-Mendieta

Role: PRINCIPAL_INVESTIGATOR

Hospital Universitario La Paz

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospital Universitario La Paz

Madrid, , Spain

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Spain

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

María Antonia Gomez-Mendieta, MD

Role: CONTACT

34917277253

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

María Antonia Gómez-Mendieta, MD

Role: primary

917277253

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HULP PI-825

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.